Aura Biosciences doses first patient in Phase 1 study of AU-011 for bladder cancer

Aura Biosciences, Inc.

First patient dosed in Phase 1 study of belzupacap sarotalocan (AU-011) for non-muscle invasive bladder cancer (NMIBC).
Phase 1 open-label trial to enroll approximately 23 adults; primary endpoint safety/tolerability.
Initial Phase 1 data expected in 2023; CMO notes no major advances in NMIBC in over two decades.
FDA granted Fast Track designation for AU-011 in NMIBC in June 2022.
Approximately 70% of bladder cancer patients are diagnosed early with NMIBC (global).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.